Abstract
BackgroundEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However, optimal sequence of treatment has yet to be defined. Overall survival (OS) is influenced by the availability/use of subsequent therapy after first-line treatment. Emergence of T790M is the main mechanism of resistance to afatinib and second-line osimertinib could be a treatment option in this instance. MethodsIn this non-interventional, global study (NCT04179890), existing medical/electronic records were identified for consecutive EGFR TKI-naïve patients with EGFR mutation-positive NSCLC (Del19 or L858R) treated with first-line afatinib and second-line osimertinib in regular clinical practice (n = 191; all T790M-positive). The primary objective was time to treatment failure (TTF). Key secondary objectives were OS and objective response rate (ORR). ResultsAt the start of afatinib treatment, median age (range) was 62 years (34–88). Fifty-five percent of patients were female and 67% were Asian. ECOG PS (0/1/≥2) was 31%/57%/12%. Fourteen percent of patients had brain metastases. At the start of osimertinib treatment, ECOG PS (0/1/≥2) was 25%/61%/14% and 14% had brain metastases (rising to 29% at the end of osimertinib treatment). The source of biopsy material (solid/liquid) was 86%/3% at the start of afatinib and 54%/33% at start of osimertinib. Mutations were mainly detected with PCR methods. Overall, median TTF was 27.7 months (95% CI: 24.0–30.2) and median OS was 36.5 months (95% CI: 32.9–41.8). ORR with afatinib and osimertinib was 74% and 45%. TTF, OS and ORR were generally consistent across subgroups. ConclusionSequential afatinib and osimertinib demonstrated encouraging activity in patients with EGFR mutation-positive NSCLC and acquired T790M. Activity was observed across all subgroups, including patients with poor ECOG PS or brain metastases. ECOG PS and incidence of brain metastases remained stable prior to, and after, afatinib treatment.
Highlights
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for the first-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) [1]
Medical and electronic health records of consecutive patients treated in a real-world practice setting who met the following criteria were retrospectively reviewed between November 2019 and July 2020: aged ≥ 18 years with EGFR mutation-positive (Del19 or L858R), TKI-naïve, advanced NSCLC treated with first-line afatinib and, following detection of T790M, second-line osimertinib
This study demonstrated promising activity of sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M
Summary
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for the first-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) [1]. How ever, to date, no head-to-head data exist that have directly compared second- and third-generation EGFR TKIs. first-line treatment of choice, in terms of which EGFR TKI to use in which patient, has not been unequivocally defined. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). Methods: In this non-interventional, global study (NCT04179890), existing medical/electronic records were identified for consecutive EGFR TKI-naïve patients with EGFR mutation-positive NSCLC (Del or L858R) treated with first-line afatinib and second-line osimertinib in regular clinical practice (n = 191; all T790M-positive).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
